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O
besity relates to the abnormal accumulation of
body fat and is associated with a number of
morbidities including diabetes, dyslipidemia,
cardiovascular disease, and cancer. Great
strides have been made in our understanding of the
molecular basis for these associations, and a number of
hypotheses have been put forward. One seemingly coun-
terintuitive hypothesis is the “adipose tissue expandability
hypothesis,” which suggests that the relative accumulation
of adipose mass per se may not be directly causative in
obesity-related metabolic abnormalities; instead, adipose
tissue function and plasticity are the key determinants.
Although adipose tissue is arguably the most plastic organ
in our bodies, it cannot expand indeﬁnitely—particularly
in the face of years of chronic fuel surplus. Furthermore,
when such a limit is reached, this would inevitably set a
limit on the body’s capacity to safely store neutral triglyc-
erides. Consequently, with continued nutritional overload,
excess fat is deposited in ectopic sites, in tissues not
specialized to store large amounts of triglycerides. The
result is lipotoxicity and metabolic dysregulation of periph-
eral tissues (1). Similar metabolic consequences may also be
predicted when one considers impaired adipose tissue func-
tion (dysregulated adipose metabolism and endocrinology)
or indeed when there is a paucity of adipose tissue.
Recent evidence points to substantial adipose tissue
remodeling, particularly in cases associated with meta-
bolic dysregulation. Obese dysfunctional adipose tissue
is characterized by adipocyte hypertrophy, increased
angiogenesis, immune inﬁltration, increased extracellu-
lar matrix deposition/ﬁbrosis, and chronic inﬂamma-
tion. In contrast, growth of healthy adipose tissue mass
is determined by a complex coordination of adipocyte
hypertrophy, adipocyte hyperplasia, adipocyte death,
and angiogenesis. Furthermore, all these events appear to
be orchestrated in a cell-type, context-dependent, and
temporal manner. Indeed, in weight stable individuals,
adipocyte turnover is thought to be balanced by the
acquisition of new adipocytes from adult adipose tissue
progenitors (mesenchymal stem cells and preadipocytes)
via adipogenesis (2). There is also evidence that this
process is titrated, presumably to appropriately match the
requirements for fuel storage, such that not all progenitors
become adipocytes simultaneously (3). What then are the
physiological signals that regulate and control adipose
tissue expansion in response to nutritional surplus? Can
these be distinguished from those pathological signals that
limit further adipose expansion?
Although much has been elucidated with regards to the
signals that regulate stem cell lineage determination, adi-
pogenesis, and angiogenesis, we know surprisingly little of
the signaling networks that coordinate all of these events
in vivo in human adipose tissue. To do so will require
knowledge of adipose cellularity under speciﬁc nutritional
and pathological circumstances. Longitudinal animal stud-
ies suggest that increases in adipocyte size precede in-
creases in adipocyte number. However, such longitudinal
data (over decades) from humans are rare. Nonetheless,
cross-sectional studies suggest that compared with nondi-
abetic obese subjects, obese diabetics have fewer but
larger adipocytes (2,4). This is consistent with reports of
an inverse correlation between differentiation capacity of
primary human progenitors/preadipocytes and BMI (5–7).
In contrast, determining the number of adipose precur-
sors (preadipocytes) in lean and obese adipose tissue has
been challenging and often resulted in seemingly contra-
dictory ﬁndings (6,7). Since different surface markers were
used to deﬁne the progenitor population, a direct compar-
ison cannot be made. One hypothesis that may reconcile
these observations differentiates multipotent adipose stem
cells (progenitors) from committed preadipocytes. It con-
siders that although the multipotent stem cell (CD133)
number is greater, the immature adipocyte or preadipo-
cyte cell number (aP2/CD68) is decreased in obese
subjects. With the recent success in identifying and locat-
ing adipose progenitors in both murine and human tissues,
it is hoped that these issues can now be addressed. Of
note, bona ﬁde multipotent adipose progenitors exhibit a
distinct molecular signature, including the expression of
stem cell markers (Lin,CD29,CD34,Sca-1,CD24),
developmental transcription factors, extracellular matrix
genes, antiangiogenic factors, and signaling cascade com-
ponents (3,8,9).
Many growth factors have been implicated in determin-
ing the size of progenitor pools (in embryonic and adult
tissue). Some, such as Wnts, bone morphogenetic proteins
(BMPs), and transforming growth factor (TGF)- have
also been implicated in regulating lineage determination
and adipogenesis, primarily in rodent models. However,
very few factors have been speciﬁcally demonstrated to
promote proliferation of human adipose progenitors. In
the accompanying original article, Zaragosi et al. (12)
present their ﬁndings on activin A, a putative promoter of
self-renewal and antiadipogenesis in human adipose
progenitors.
Activins are members of the TGF- protein superfamily
of secreted growth factors, which includes BMPs, Nodal,
and TGF-. They act in a paracrine/autocrine manner to
regulate cell proliferation, differentiation, and apoptosis
during embryonic development, tissue remodeling, inﬂam-
matory immune response, wound repair, and reproduc-
tion. Activins exist in a number of dimeric conﬁgurations,
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tivin A is a homodimer of inhibin A subunits encoded by
the INHBA gene. Similarly, activins B, C, and E are
homodimers of INHBB, INHBC, and INHBE gene prod-
ucts, respectively. Activin AB is heterodimer of inhibin A
and inhibin B subunits. Interestingly, the inhibin A
subunit is widely expressed, whereas the inhibin B
subunit is highly expressed in adipocytes, and the C and
E subunits are predominantly expressed in the liver. To
date, only activin B and activin E homodimers have been
implicated in glucose homeostasis (10,11).
Zaragosi et al. now report that INHBA mRNA is not only
detected in human adipose tissue, but unlike INHBB,i ti s
preferentially expressed in primary adipose progenitors
(human multipotent adipose-derived stem [hMADS] cells
and CD34/CD31 stromal vascular fraction [SVF] cells)
and localized to SVFs of omental, subcutaneous, and
mesenteric white adipose depots. In vitro, activin A ex-
pression and secretion is required for optimal proliferation
during cell propagation, but it is downregulated as cul-
tured hMADS and primary human preadiocytes undergo
adipogenic conversion (12). Although this observation
seems consistent with the known mitogenic action of
activin A (on embryonic and gonadal stem cells), it con-
trasts with a lack of effect on clonal expansion during
murine preadipocyte differentiation (13,14).
As with most “preadipocyte” genes, activin A can inhibit
adipogenesis in vitro (12–14). However, its mechanism of
action seems to be context dependent. Previous reports
have suggested that activin A targets CCAAT/enhancer-
binding protein  (C/EBP) activity (13,15). In contrast,
Zaragosi et al. suggest that activin A prevents adipogenic
induction of both C/EBP isoforms (LAP and LIP). They
further support this with evidence that C/EBP-LAP over-
expressing hMADS cells are resistant to the antiadipogenic
actions of activin A (12). Futher mechanistic insights are
provided using both pharmacological inhibition of activin
receptor kinase activity (ALK inhibitor SB-431542), as well
as SMAD2 small interfering RNA. This is not only consis-
tent with the limited knowledge of activin A–mediated
signal transduction (Fig. 1), but also demonstrates that
these signal tranducers are involved in activin A–induced
proliferaton and antiadipogenesis in hMADS. What still
remains unclear is the identity of the activin-induced
SMAD2 target genes that inhibit C/EBP expression
and/or promote proliferation. Moreover, given the roles of
activin A in nonadipose lineage determination (16,17), it
also remains to be formally demonstrated that activin A
does not alter the multipotency of human adipose progen-
itors. If multipotency of progenitors is lost after activin A
treatment, this could represent the alternative possibility
that in obese-inﬂamed adipose tissue, activin A plays a role
in reducing adipogenic potential of progenitors but also
promotes tissue ﬁbrosis.
Zaragosi et al. also found that in the white adipose tissue
of obese nondiabetic individuals, INHBA expression was
FIG. 1. Activin A–mediated signal transduction promotes cell proliferation and inhibits adipogenesis. Activin receptor speciﬁcities and
intracellular signal transducers appear complex and incompletely delineated, in part because activin A receptors can also transduce signals of
other TGF- superfamily members. They may also be tissue- and context-speciﬁc. Nonetheless, activin A has been reported to bind both type IIA
(activin receptor type-2A; ActRIIA or ACVR2A) and type IIB (activin receptor type-2B; ActRIIB or ACVR2B) surface receptors. This
receptor-ligand interaction leads to the recruitment, transphosphorylation, and activation of the type I activin receptor (ACVR1B or ALK-4). The
receptor then interacts with and phosphorylates cytoplasmic SMAD2, which multimerizes with SMAD4 and translocates to the nucleus where
these proteins can act as transcription factor complexes to induce a subset of genes implicated in stem cell renewal or differentiation. SMAD2
is required to promote activin A–induced cell proliferation and to suppress adipogeic expression of C/EBP.
J.K. SETHI
diabetes.diabetesjournals.org DIABETES, VOL. 59, OCTOBER 2010 2355FIG. 2. Local autocrine and paracrine signals regulate progenitor proliferation and titrate adipogenesis. Remarkable parallels are emerging
between the Wnt/-catenin signaling network (A) and the activin signaling network (B). These suggest that maturing adipocytes may produce
proadipogenic signals that inhibit progenitor proliferation and promote preadipocyte recruitment.
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it is not clear whether these subjects are exhibiting the
early hallmarks of adipose tissue inﬂammation. Further
investigation suggests that in progenitors, activin A was
induced by signals secreted from adipose tissue–derived
CD34/CD14 cells (i.e., macrophages, monocytes, and
polymorphonuclear neutrophils). Given that activin A is
known to be regulated by proinﬂammatory cytokines (18),
this potentially provides additional support for the notion
that a proinﬂammatory environment contributes to limit-
ing further adipose expansion (19). An additional fascinat-
ing observation is that activin A expression in adipose
progenitors is reduced by the synthetic glucocorticoid
dexamethasone. This presents the intriguing possibility
that anti-inﬂammatory steroids may promote adiposity, in
part, via downregulation of INHBA.
As with any new discovery, the report by Zaragosi et al.
raises many new questions. For example, if activin A is
important in the physiological regulation of adipose tissue
growth, is its production regulated by nutritional cues and
during the development of normal adiposity? How does
the presence of proadipogenic activin B (from adipocytes)
affect activin A bioactivity in adipose progenitors? Does
the activin network mediate the paracine cross talk be-
tween maturing adipocytes and preadipocytes as has been
proposed for the Wnt network (Fig. 2 and ref. 20).
Given its ubiquitous expression and diverse biological
functions, a detailed understanding of local/tissue-speciﬁc
regulation of activin A activity is also required before we
can consider it as a candidate for antiobesity therapeutics.
In obesity, what proportions of adipose-derived activin A
contribute to circulating levels? Are these levels inﬂu-
enced by sex or reproductive age, liver dysfunction or
cancer? Does adipose expression and activity of activin A
correlate inversely with adiposity, particularly in the ab-
sence of adipose inﬂammation? Is it differentially ex-
pressed in adipose tissue from obese healthy subjects
relative to obese diabetic subjects? Finally, because the
biological activity and bioavailability of activin A is inﬂu-
enced by the presence of functional antagonists and
binding proteins, such as inhibins and follistatin (14), it
will be pertinent to deﬁne the in vivo levels of activins,
follistatin, and inhibins in the same subjects before making
any inferences as to the potential consequences of differ-
ential expression in lean, obese, and obese-diabetic adi-
pose tissue.
In summary, given that limitations in fat storage can lead
to metabolic disorders, there is a clear need to decode the
molecular mechanisms that regulate adipose tissue ex-
pandability and to discriminate between the normal phys-
iological cues and those involved in the metabolic
syndrome. Clearly, unlocking adipose-speciﬁc signals that
prevent adipose progenitors from differentiating in re-
sponse to nutritional surplus is attractive for biomarker
discovery, targeted therapeutics, and tissue engineering
alike. However, much remains to be addressed before
activin A can be proposed as a candidate biomarker for
obesity and/or a therapeutic target for the associated
metabolic complications.
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